Chemical Industry ; Humans ; Occupational Exposure ; Risk Assessment

Air ; analysis ; Chromatography ; methods ; Ions ; analysis ; Metals, Alkali ; analysis ; Workplace

Hydrogen Peroxide ; analysis ; Sensitivity and Specificity ; Spectrophotometry ; methods ; Titanium ; Workplace

Benzene ; DNA Damage ; Humans ; Research

Adult ; Child ; DDT ; analysis ; blood ; Environmental Pollution ; prevention & control ; Female ; Humans ; Male ; Milk, Human ; chemistry ; Young Adult

Animals ; Dose-Response Relationship, Drug ; Female ; Male ; Rats ; Rats, Sprague-Dawley ; Toluene 2,4-Diisocyanate ; metabolism ; pharmacokinetics ; urine

Humans ; Occupational Diseases ; epidemiology ; Quality Control ; Risk Assessment

Adult ; Drug-Related Side Effects and Adverse Reactions ; Female ; Humans ; Medical Staff, Hospital ; Occupational Exposure ; Surveys and Questionnaires ; Women's Health

Objective To explore the increasing risk of herpes zoster and its possible mechanisms for hematologic disorders treated with arsenic trioxide (ATO). Methods The cases were divided into study group (with ATO) and control group (without ATO). The incidence rate of herpes zoster was compared between the two groups, and then the average cycles of chemotherapy were compared between the patients complicated with herpes zoster or not in study group. Results The rate of herpes zoster was significantly higher in study group than that in control group (χ2 =4.492, P =0.034). The rates of herpes zoster were 23.95 % (23/96) in study group and 7.89 % (3/38) in control groups. Patients in study group with herpes zoster had received 7.60 cycles and those without herpes zoster 7.72 cycles of chemotherapy on average (Z=0.976, P=0.296).Conclusion The risk of herpes zoster complication in hematologic disorders was increased after ATO treatment which probably activated varicella-zoster virus.

OBJECTIVETo investigate the inhibitory effects of CD36-targeting RNA interference on the latent transforming growth factor β1 (L-TGF-β1) activation and silicotic fibrosis in rat silicosis model.

METHODSWistar rats were divided into four groups: saline control group (n=24), SiO2 model group (10 mg SiO2 per rat) (n=24), SiO2+Lv-shCD36 group (lentiviral vector expressing specific shRNA against CD36) (n=24), and SiO2+Lv-shCD36-NC group (non-silence control lentivirus) (n=24). At 7, 21, and 28 d after instillation, the rats were sacrificed. The activity of TGF-β1 in bronchoalveolar lavage fluid (BALF) was measured by evaluating its inhibitory effect on the proliferation of mink lung epithelial cells. The pathological changes of lung tissue were observed by HE staining and van Gieson staining. The hydroxyproline content in the lungs was determined by alkaline lysis method.

RESULTSAt 7 d after instillation, the expression of CD36 mRNA in alveolar macrophages was significantly lower in the SiO2+Lv-shCD36 group than in the saline control group, SiO2 model group, and SiO2+Lv-shCD36-NC group (P < 0.05); the quantity and percentage of active TGF-β1 in BALF were significantly lower in the SiO2+Lv-shCD36 group than in the SiO2 model group and SiO2+Lv-shCD36-NC group (P < 0.05). At 28 d after instillation, there were cellular silicotic nodules in the lungs of rats in SiO2+Lv-shCD36 group and fibrotic cellular silicotic nodules in the lungs of rats in SiO2 model group and SiO2+Lv-shCD36-NC group. At 21 and 28 d after instillation, the hydroxyproline content was significantly lower in the SiO2+Lv-shCD36 group than in the SiO2 model group and SiO2+Lv-sh CD36-NC group (P < 0.05).

CONCLUSIONCD36-targeting RNA interference has inhibitory effects on the L-TGF-β1 activation and silicotic fibrosis in rat silicosis model.

Animals ; Bronchoalveolar Lavage Fluid ; chemistry ; CD36 Antigens ; genetics ; metabolism ; Disease Models, Animal ; Female ; Hydroxyproline ; chemistry ; Macrophages, Alveolar ; metabolism ; Male ; RNA Interference ; Rats ; Rats, Wistar ; Silicon Dioxide ; toxicity ; Silicosis ; metabolism ; prevention & control ; Transforming Growth Factor beta1 ; metabolism